In this regard, one of our groups first demonstrated that an enhanced CD103+ TIL subset correlates with improved early-stage non-small-cell lung carcinoma (NSCLC) patient survival [27]. This evidence concerns the gene ITGAE and non-small cell lung carcinoma.